BACKGROUND: Adolescent and adult patients with neuroblastoma appear to have a more indolent disease course but a lower survival rate compared with their younger counterparts. The majority of neuroblastoma tumors specifically accumulate the radiolabeled norepinephrine analogue iodine-131-metaiodobenzylguanidine ((131) I-MIBG). Therefore, (131) I-MIBG has become increasingly used as targeted radiotherapy for patients with recurrent or refractory neuroblastoma. The objective of the current study was to characterize the toxicity and activity of this therapy in older patients. METHODS: The authors performed a retrospective analysis of 39 consecutive patients aged ≥10 years with recurrent or refractory neuroblastoma who were treated with (131) I-MIBG monotherapy at the University of California at San Francisco under phase 1, phase 2, and compassionate access protocols. RESULTS: Sixteen patients were aged ≥18 years at the time of MIBG treatment initiation, whereas 23 patients were ages 10 to 17 years. The median cumulative administered dose of (131) I-MIBG was 17.8 millicuries (mCi)/kg. The majority of treatments led to grade 3 or 4 hematologic toxicities (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 3]) that were similar in frequency among age strata. Three patients subsequently developed a hematologic malignancy or myelodysplasia. The overall rate of complete plus partial response was 46%. Patients aged ≥18 years at the time of first MIBG treatment had a significantly higher response rate compared with patients ages 10 to 17 years (56% vs 39%; P = .023). The median overall survival was 23 months with a trend toward longer overall survival for the subgroup of patients aged ≥18 years (P = .12). CONCLUSIONS: The findings of the current study suggest that (131) I-MIBG is a highly effective salvage agent for adolescents and adults with neuroblastoma.
BACKGROUND: Adolescent and adult patients with neuroblastoma appear to have a more indolent disease course but a lower survival rate compared with their younger counterparts. The majority of neuroblastoma tumors specifically accumulate the radiolabeled norepinephrine analogue iodine-131-metaiodobenzylguanidine ((131) I-MIBG). Therefore, (131) I-MIBG has become increasingly used as targeted radiotherapy for patients with recurrent or refractory neuroblastoma. The objective of the current study was to characterize the toxicity and activity of this therapy in older patients. METHODS: The authors performed a retrospective analysis of 39 consecutive patients aged ≥10 years with recurrent or refractory neuroblastoma who were treated with (131) I-MIBG monotherapy at the University of California at San Francisco under phase 1, phase 2, and compassionate access protocols. RESULTS: Sixteen patients were aged ≥18 years at the time of MIBG treatment initiation, whereas 23 patients were ages 10 to 17 years. The median cumulative administered dose of (131) I-MIBG was 17.8 millicuries (mCi)/kg. The majority of treatments led to grade 3 or 4 hematologic toxicities (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 3]) that were similar in frequency among age strata. Three patients subsequently developed a hematologic malignancy or myelodysplasia. The overall rate of complete plus partial response was 46%. Patients aged ≥18 years at the time of first MIBG treatment had a significantly higher response rate compared with patients ages 10 to 17 years (56% vs 39%; P = .023). The median overall survival was 23 months with a trend toward longer overall survival for the subgroup of patients aged ≥18 years (P = .12). CONCLUSIONS: The findings of the current study suggest that (131) I-MIBG is a highly effective salvage agent for adolescents and adults with neuroblastoma.
Authors: Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel Journal: N Engl J Med Date: 2010-09-30 Impact factor: 91.245
Authors: J Treuner; U Feine; D Niethammer; W Müller-Schaumburg; J Meinke; E Eibach; R Dopfer; T Klingebiel; S Grumbach Journal: Lancet Date: 1984-02-11 Impact factor: 79.321
Authors: Alberto Garaventa; Claudio Gambini; Giampiero Villavecchia; Andrea Di Cataldo; Luigi Bertolazzi; Maria Rosa Pizzitola; Bruno De Bernardi; Riccardo Haupt Journal: Cancer Date: 2003-03-01 Impact factor: 6.860
Authors: Steven G DuBois; Julia Messina; John M Maris; John Huberty; David V Glidden; Janet Veatch; Martin Charron; Randall Hawkins; Katherine K Matthay Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: Sean Carlin; Rob J Mairs; Anthony G McCluskey; Deborah A Tweddle; Alan Sprigg; Christine Estlin; Julian Board; Rani E George; Caroline Ellershaw; Andrew D J Pearson; John Lunec; Paolo G Montaldo; Mirco Ponzoni; Berthe L van Eck-Smit; Cees A Hoefnagel; Marieke D van den Brug; Godelieve A M Tytgat; Huib N Caron Journal: Clin Cancer Res Date: 2003-08-15 Impact factor: 12.531
Authors: Dana C Baiu; Ian R Marsh; Alexander E Boruch; Ankita Shahi; Saswati Bhattacharya; Justin J Jeffery; Qianqian Zhao; Lance T Hall; Jamey P Weichert; Bryan P Bednarz; Mario Otto Journal: J Nucl Med Date: 2017-07-26 Impact factor: 10.057
Authors: Margaret J Zhou; Michelle Y Doral; Steven G DuBois; Judith G Villablanca; Gregory A Yanik; Katherine K Matthay Journal: Eur J Cancer Date: 2015-08-05 Impact factor: 9.162
Authors: Cihan Cetinkaya; Tommy Martinsson; Johanna Sandgren; Catarina Träger; Per Kogner; Jan Dumanski; Teresita Díaz de Ståhl; Fredrik Hedborg Journal: BMC Cancer Date: 2013-05-09 Impact factor: 4.430
Authors: Ana P Berbegall; Eva Villamón; Irene Tadeo; Tommy Martinsson; Adela Cañete; Victoria Castel; Samuel Navarro; Rosa Noguera Journal: Neoplasia Date: 2014-06 Impact factor: 5.715